Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319460108> ?p ?o ?g. }
- W4319460108 endingPage "1695" @default.
- W4319460108 startingPage "1685" @default.
- W4319460108 abstract "Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE). This study assessed the efficacy and side effects of HCQ in children with proliferative lupus nephritis (LN). This double-blind, randomized, placebo-controlled trial study was conducted on 60 children with proliferative LN classes III and IV treated with steroids and a mycophenolate (MMF) regimen. Patients were categorized into two groups, the HCQ group (n = 30) and the placebo group (n = 30). They were evaluated initially at 6- and a 12-month follow-up by mucocutaneous, ophthalmological examination, and investigations (BUN, creatinine, 24 h proteinuria, triglycerides (TG), cholesterol, Antids-DNA, C3, C4). Disease activity was assessed using the SLE disease activity index (SLEDAI-2 k). After 12 months, TG, cholesterol, 24 h proteinuria, Antids-DNA, and SLEDAI score were significantly decreased in the HCQ group (P: 0.002, 0.012, 0.031, 0.001, respectively). After 12 months, the cumulative probabilities of developing primary end-points (LN partial and complete remission) were 40% and 60% in the HCQ group versus 53.3% and 36.7% in the placebo group (P: 0.002). After 12 months, the HCQ group experienced mucocutaneous alopecia (3.3%), hyperpigmentation (10%), and ophthalmological mild retinal changes (6.7%), but they did not differ significantly from the placebo group. Cunclusion: HCQ improved the disease and LN activity in children with proliferative LN, with documented skin hyperpigmentation and mild retinal changes following HCQ use in a few cases. This study was registered on http://www.gov/ with trial registration number (TRN): NCT03687905, September 2018 retrospectively registered.• Hydroxychloroquine (HCQ) is documented as an adjunctive treatment in children with systemic lupus erythematosus (c-SLE) LN with efficacy in improving lupus musculoskeletal and mucocutaneous manifestations. • Due to the paucity of studies, its effects and side effects in children with LN remain unclear.• This pilot randomized clinical trial assessed the efficacy and adverse effects of HCQ in children with proliferative LN. • HCQ had numerous advantages for LN, including rapid and sustained remission, antilipidemic effect, and rapid improvement of kidney functions." @default.
- W4319460108 created "2023-02-09" @default.
- W4319460108 creator A5003865308 @default.
- W4319460108 creator A5005582292 @default.
- W4319460108 creator A5007198437 @default.
- W4319460108 creator A5058697460 @default.
- W4319460108 creator A5075444249 @default.
- W4319460108 date "2023-02-08" @default.
- W4319460108 modified "2023-09-27" @default.
- W4319460108 title "Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial" @default.
- W4319460108 cites W1780879115 @default.
- W4319460108 cites W1803284676 @default.
- W4319460108 cites W1982134628 @default.
- W4319460108 cites W1983493239 @default.
- W4319460108 cites W2014873778 @default.
- W4319460108 cites W2015040567 @default.
- W4319460108 cites W2024228574 @default.
- W4319460108 cites W2035752671 @default.
- W4319460108 cites W2038511894 @default.
- W4319460108 cites W2084136584 @default.
- W4319460108 cites W2095161148 @default.
- W4319460108 cites W2119483296 @default.
- W4319460108 cites W2144514841 @default.
- W4319460108 cites W2169270824 @default.
- W4319460108 cites W2175478656 @default.
- W4319460108 cites W2225742804 @default.
- W4319460108 cites W2409803365 @default.
- W4319460108 cites W2414716738 @default.
- W4319460108 cites W2471395144 @default.
- W4319460108 cites W2511532406 @default.
- W4319460108 cites W2560774983 @default.
- W4319460108 cites W2743235681 @default.
- W4319460108 cites W2744484065 @default.
- W4319460108 cites W2753260601 @default.
- W4319460108 cites W2768281634 @default.
- W4319460108 cites W2786833650 @default.
- W4319460108 cites W2805703748 @default.
- W4319460108 cites W2993632753 @default.
- W4319460108 cites W3013081823 @default.
- W4319460108 cites W3111410893 @default.
- W4319460108 cites W4200181143 @default.
- W4319460108 doi "https://doi.org/10.1007/s00431-023-04837-0" @default.
- W4319460108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36752895" @default.
- W4319460108 hasPublicationYear "2023" @default.
- W4319460108 type Work @default.
- W4319460108 citedByCount "1" @default.
- W4319460108 countsByYear W43194601082023 @default.
- W4319460108 crossrefType "journal-article" @default.
- W4319460108 hasAuthorship W4319460108A5003865308 @default.
- W4319460108 hasAuthorship W4319460108A5005582292 @default.
- W4319460108 hasAuthorship W4319460108A5007198437 @default.
- W4319460108 hasAuthorship W4319460108A5058697460 @default.
- W4319460108 hasAuthorship W4319460108A5075444249 @default.
- W4319460108 hasBestOaLocation W43194601081 @default.
- W4319460108 hasConcept C126322002 @default.
- W4319460108 hasConcept C134018914 @default.
- W4319460108 hasConcept C142724271 @default.
- W4319460108 hasConcept C156662089 @default.
- W4319460108 hasConcept C203014093 @default.
- W4319460108 hasConcept C204787440 @default.
- W4319460108 hasConcept C27081682 @default.
- W4319460108 hasConcept C2776912625 @default.
- W4319460108 hasConcept C2778653478 @default.
- W4319460108 hasConcept C2779123688 @default.
- W4319460108 hasConcept C2779134260 @default.
- W4319460108 hasConcept C2779561371 @default.
- W4319460108 hasConcept C2779912601 @default.
- W4319460108 hasConcept C2780091579 @default.
- W4319460108 hasConcept C2780306776 @default.
- W4319460108 hasConcept C2781184683 @default.
- W4319460108 hasConcept C3008058167 @default.
- W4319460108 hasConcept C524204448 @default.
- W4319460108 hasConcept C555293320 @default.
- W4319460108 hasConcept C71924100 @default.
- W4319460108 hasConcept C90924648 @default.
- W4319460108 hasConceptScore W4319460108C126322002 @default.
- W4319460108 hasConceptScore W4319460108C134018914 @default.
- W4319460108 hasConceptScore W4319460108C142724271 @default.
- W4319460108 hasConceptScore W4319460108C156662089 @default.
- W4319460108 hasConceptScore W4319460108C203014093 @default.
- W4319460108 hasConceptScore W4319460108C204787440 @default.
- W4319460108 hasConceptScore W4319460108C27081682 @default.
- W4319460108 hasConceptScore W4319460108C2776912625 @default.
- W4319460108 hasConceptScore W4319460108C2778653478 @default.
- W4319460108 hasConceptScore W4319460108C2779123688 @default.
- W4319460108 hasConceptScore W4319460108C2779134260 @default.
- W4319460108 hasConceptScore W4319460108C2779561371 @default.
- W4319460108 hasConceptScore W4319460108C2779912601 @default.
- W4319460108 hasConceptScore W4319460108C2780091579 @default.
- W4319460108 hasConceptScore W4319460108C2780306776 @default.
- W4319460108 hasConceptScore W4319460108C2781184683 @default.
- W4319460108 hasConceptScore W4319460108C3008058167 @default.
- W4319460108 hasConceptScore W4319460108C524204448 @default.
- W4319460108 hasConceptScore W4319460108C555293320 @default.
- W4319460108 hasConceptScore W4319460108C71924100 @default.
- W4319460108 hasConceptScore W4319460108C90924648 @default.
- W4319460108 hasFunder F4320324798 @default.
- W4319460108 hasIssue "4" @default.